First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors

Maria Martinez-Garcia, Udai Banerji, Joan Albanell, Rastilav Bahleda, Saoirse Dolly, Françoise Kraeber-Bodéré, Federico Rojo, Emilie Routier, Ernesto Guarin, Zhi Xin Xu, Ruediger Rueger, Jean J.L. Tessier, Eliezer Shochat, Steve Blotner, Valerie Meresse Naegelen, Jean Charles Soria

Research output: Contribution to journalArticleResearchpeer-review

104 Citations (Scopus)

Fingerprint

Dive into the research topics of 'First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors'. Together they form a unique fingerprint.

Medicine & Life Sciences